Pathology: non squamous - mNSCLC - L1 - Wild Type (WT);
| non squamous - mNSCLC - L1 - Wild Type (WT) | |||
| KEYNOTE-021, 2016 | KEYNOTE-189, 2018 | ||
| pembrolizumab plus SoC | 1 | T1 | |
| pembrolizumab and pemetrexed plus platin | 1 | T1 | |
| placebo plus SoC | 0 | T0 | |
| pemetrexed plus platin | 0 | T0 |